The development of litifilimab (BIIB 059) for cutaneous and systemic lupus erythematosus.
Immunotherapy
; 16(1): 15-20, 2024 Jan.
Article
in En
| MEDLINE
| ID: mdl-37877249
This review discusses a new medicine in development for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Known as litifilimab, it binds to a protein that is only found on a specific type of cell called a plasmacytoid dendritic cell (pDC). Although all people have pDCs, patients with SLE or CLE have large amounts of these cells in certain organs, such as their skin, kidneys and joints. Since pDCs make substances that promote inflammation and contribute to some of the manifestations of SLE and CLE, litifilimab was designed to prevent these cells from making such substances. One of the key substances made by pDCs whose synthesis is blocked by litifilimab is called interferon. The article describes how litifilimab works, discusses the studies performed to date and outlines the path forward to determine if litifilimab will ultimately be a drug that clinicians can use to treat patients with SLE or CLE.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lupus Erythematosus, Cutaneous
/
Interferon Type I
/
Lupus Erythematosus, Systemic
Limits:
Humans
Language:
En
Journal:
Immunotherapy
Journal subject:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Year:
2024
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom